Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial

Journal of Neural Transmission

Volumn 103, Issue 8-9, 1996, Pages 1105-1116

  Zemlan, F P ^a   Folks, D G ^a,b   Goldstein, B J ^a,c   Gottlieb, G ^a,d   Holub, R F ^a,e   Linden, R D ^a,f   Margolin, R A ^a,g   Richter, R W ^a,h   Speakman, W F ^a,i   Strub, R L ^a,j  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Dominion Towers   (United States)

^d Ralston Penn Center   (United States)

^e Neurologic Associates Albany   (United States)

^f Psychopharmacology Res Institute   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h Clinical Pharmaceutical Trials Inc   (United States)

ⁱ Alzheimer's Diagnostic Clinic   (United States)

^j OCHSNER MEDICAL CENTER   (United States)

more..

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Psychparmacology; Velnacrine

Indexed keywords

AMINOTRANSFERASE; CHOLINESTERASE INHIBITOR; VELNACRINE;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLACEBOS; TACRINE; TREATMENT OUTCOME;

EID: 10544234610     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01291795     Document Type: Article

References (32)

1. Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979) Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135: 216-223
2. Antuono PG (1995) Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. Arch Intern Med 155: 1766-1772
3. Bleeker ML, Bolla-Wilson K, Kawas C, Agnew J (1988) Age-specific norms for the mini-mental state exam. Neurology 38: 1565-1568
4. Blessed G, Tomlinson BE, Roth M (1968) The association between quantitative measures of dementia and of senile changes in the cerebral grey matter of elderly subjects. Br J Psychiatry 114: 797-811
5. Bowen DM (1983) Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease. In: Katzman R (ed) Banbury report 15: biological aspects of Alzheimer's disease. Cold Spring Harbor Laboratory, New York, pp 219-231
6. Breteler MMB, Claus JJ, van Duijn CM, Launer LJ, Hofman A (1992) Epidemiology of Alzheimer's disease. Epidemiol Rev 14: 59-82
7. Chan-Palay V (1990) Depression and senile dementia of the Alzheimer type: catecholamine changes in the locus coeruleus - basis for therapy. Dementia 1: 253-261
8. Coyle JT, Price DC, DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219: 1184-1190
9. Cross AJ, Crow TJ, Perry EK, Perry RH, Blessed G, Tomlinson BE (1981) Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J 282: 93-94
10. Cross AJ, Crow TJ, Johnson JA, et al (1983) Monoamine metabolism in senile dementia of Alzheimer type. J Neurol Sci 60: 383-392
11. Davies P (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet: 1403
12. Davies P (1979) Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 171: 319-327
13. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowski C, Dolan-Ureno J (1992) A controlled trial of tacrine in Alzheimer's disease. J Am Med Assoc 268: 2523-2529
14. Folstein M, Folstein S, McHugh PR (1975) Mini-mental state: a practical method of grading the cognitive state of patients for the clinician. J Psychiatry Res 12: 189-198
15. Francis PT, Palmer AM, Sims NR, et al (1985) Neurochemical studies of early-onset Alzheimer's disease. N Engl J Med 313: 7-11
16. Goa KL, Fitton A (1994) Velnacrine in Alzheimer's disease: an initial appraisal of its clinical potential. CNS Drugs 1: 232-240
17. Growdon JH (1992) Treatment for Alzheimer's disease? N Engl J Med 327: 1306-1308
18. Guy W (1976) Clinical global impressions. In: Guy W (ed) ECDEU assessment manual for psychopharmacology, rev ed. Department of Health, Education, and Welfare Rockville, Md, [DHEW publication no (ADM) 76-338], pp 218-222
19. Kramer-Ginsberg E, Mohs RC, Aryan M, et al (1984) Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 24: 458-462
20. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. J Am Med Assoc 271: 985-991
21. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 176-186
22. Marchbanks RM (1982) Biochemistry of Alzheimer's dementia. J Neurochem 39: 9-15
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 34: 939-944
24. Murphy MF, Hardiman ST, Nash RJ, et al (1991) Evaluation of HP 029 (velnacrine maleate) in Alzheimer's Disease. Ann NY Acad Sci 640: 253-262
25. Perry EK (1987) Cortical neurotransmitter chemistry in Alzheimer's disease. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 887-895
26. Reisberg B, Ferris SH, De Leon MJ, Crook T (1982) The global deterioration scale for assessment of primary dementia. Am J Psychiatry 139: 1136-1139
27. Reisine TD, Yamamura HI, Bird ED, Spokes E, Enna SJ (1978) Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res 159: 477-481
28. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364
29. Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL (1980) Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci Lett 20: 373-377
30. SAS Institute (1990) SAS/STAT User's guide. Version 6,4th ed. SAS Institute Inc, Cary, NC
31. Siegfried K, Murphy MF (1993) The cholinergic approach to the treatment of Alzheimer's disease. In: Wolters EC, Scheltens P (eds) Alzheimer's disease: back to the future. Universitelt, Amsterdam, pp 97-106
32. Sims NR, Bowen DM, Allen SJ, et al (1983) Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 40: 503-509